ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2698

Renal Involvement in Mixed Connective Tissue Disease: A Single Center Experience

Eduardo Martín Nares1, Silvia Eunice Ramírez Andrade2, Luis Eduardo Morales Buenrostro2, Norma Ofelia Uribe Uribe3, Laura R Cárdenas M3, Montserrat Reyes Macedo3 and Tatiana S. Rodriguez-Reyna1, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Department of Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 3Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: glomerulonephritis, Mixed connective tissue disease (MCTD), Nephritis, renal disease and ribonucleoprotein (RNP)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Sclerosis and Related Disorders – Clinical Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Kidney injury in mixed connective tissue disease (MCTD) is an uncommon manifestation. Prevalence has been reported to be <4% in some cohorts. The frequency of renal involvement in Hispanic patients with MCTD is not known. We aimed to describe the prevalence, clinical characteristics and outcomes of renal involvement in Mexican patients with MCTD.

Methods: We conducted a retrospective single-center study. We included patients with a diagnosis of MCTD according to the Alarcón-Segovia criteria who regularly attended to a referral center in Mexico City (2003-2017) and we identified those with renal involvement defined as proteinuria >500 mg/d with or without active sediment, creatinine elevation 50% above baseline or development of glomerular filtration rate (GFR) <60 ml/min, with no other known cause. We collected demographics, clinical manifestations, follow-up time, treatment, outcomes and damage (SLICC/ACR-DI), renal function, serological and histological variables.

Results: One hundred and thirty one patients with MCTD were followed at our center. We identified 14 patients with renal involvement with a prevalence of 10.7%. Among those patients, 13 were women (92.8%); mean age at onset of renal involvement was 44 ± 8 years. Most frequent manifestations were Raynaud’s phenomenon in 13 (92.8%) patients, arthritis in 12 (85.7%), puffy hands in 12 (85.7%), sclerodactily in 8 (77.1%), sicca syndrome in 8 (77.1%) and myositis in 7 (50%). Median time elapsed from MCTD diagnosis to renal involvement was 83 (2-365) months. In 3 patients, renal involvement was present at MCTD onset. Seven (50%) patients had other signs of MCTD activity at the time of renal involvement onset. Four (28.5%) patients presented with sub-nephrotic proteinuria, 3 (21.4%) with nephrotic range proteinuria and kidney injury, 2 (14.3%) with sub-nephrotic proteinuria and kidney injury, 2 (14.3%) with nephrotic range proteinuria, 1 only with nephrotic range proteinuria and 1 (7.1%) with end-stage renal disease. Microscopic hematuria was present in 9 (64.3%) patients and leukocyturia in 6 (42.8%). Renal biopsy was performed in 8 (57%) patients; pathological diagnoses were: crescentic and necrotizing glomerulonephritis (GN) (2 patients; one of these patients developed positive ANCA antibodies), membranous GN (2), GN ISN/RPS 2003 class III + V (1), GN ISN/RPS 2003 class IV and vasculopathy (1), minimal mesangial GN (1) and chronic tubulointerstitial nephritis with vasculopathy (1). Ten (71.4%) patients achieved either total or partial remission at a median follow up of 82 (1-367) months. Only one patients required dialysis. At last follow up the median SLICC/ACR-DI was 1.5 (0-4) points. Two patients died.

Conclusion: In our cohort of MCTD patients, prevalence of renal involvement was low, although higher than the one reported in other populations. Clinical presentation and pathological diagnoses were diverse. Renal biopsy was helpful, since glomerulonephritis, vasculopathy and overlap with ANCA associated vasculitis were found in several patients; these options should be considered in the differential diagnoses of MCTD patients with renal involvement.


Disclosure: E. Martín Nares, None; S. E. Ramírez Andrade, None; L. E. Morales Buenrostro, None; N. O. Uribe Uribe, None; L. R. Cárdenas M, None; M. Reyes Macedo, None; T. S. Rodriguez-Reyna, None.

To cite this abstract in AMA style:

Martín Nares E, Ramírez Andrade SE, Morales Buenrostro LE, Uribe Uribe NO, Cárdenas M LR, Reyes Macedo M, Rodriguez-Reyna TS. Renal Involvement in Mixed Connective Tissue Disease: A Single Center Experience [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/renal-involvement-in-mixed-connective-tissue-disease-a-single-center-experience/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/renal-involvement-in-mixed-connective-tissue-disease-a-single-center-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology